Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 29;18(2):270. doi: 10.3390/ijms18020270

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(a) Adoptive immunotherapy (AIT) against 4T1 subcutaneous tumors with T cells activated with B/I and cultures in IL-2, IL-21, IL-2/21, IL-7/15, IL-7/15/21. Recipient BALB/c mice were injected in the flank with 10⁴ 4T1 cells and randomized into seven treatment groups: untreated control, cyclophosphamide (CYP)-only (100 mg/kg), and CYP + AIT with B/I activated DLN cells from 4T1-sensitized BALB/c mice cultured in IL-2, IL-21, IL-2/21, IL-7/15 or IL-7/15/21 (50 × 10⁶ cells/mouse). CYP was given 3 days after tumor inoculation and cultured lymphocytes were infused intravenously (IV) the following day (day 4). Mean tumor sizes +/− standard error are charted over time (in days). Numbers in parentheses to the right indicate the number of mice with complete tumor regression (cure) per total number of mice in each group; (b) Adoptive immunotherapy (AIT) against 4T1 subcutaneous tumors with T cells activated with B/I and cultures in IL-2, IL-21, IL-2/21, IL-7/15, IL-7/15/21 at a lower dose (10 million cells/mouse), averaged over three experiments. Recipient BALB/c mice were injected in the flank with 10⁴ 4T1 cells and randomized into seven treatment groups: untreated control, cyclophosphamide (CYP)-only (100 mg/kg), and CYP + AIT with B/I activated DLN cells from 4T1-sensitized BALB/c mice cultured in IL-2, IL-21, IL-2/21, IL-7/15 or IL-7/15/21 (10 × 10⁶ cells/mouse). CYP was given 3 days after tumor inoculation and cultured lymphocytes were infused IV the following day (day 4). Mean tumor sizes +/− standard error are charted over time (in time points which represent a 2–3 day time period); (c) Adoptive immunotherapy (AIT) against 4T1 subcutaneous tumors with T cells activated with B/I and cultures in IL-2, IL-21, IL-2/21, IL-7/15, IL-7/15/21 with initial larger tumor (7 day tumor) averaged over two experiments. Recipient BALB/c mice were injected in the flank with 10⁴ 4T1 cells and randomized into seven treatment groups: untreated control, cyclophosphamide (CYP)-only (100 mg/kg), and CYP + AIT with B/I activated DLN cells from 4T1-sensitized BALB/c mice cultured in IL-2, IL-21, IL-2/21, IL-7/15 or IL-7/15/21 (10 × 10⁶ cells/mouse). CYP was given 6 days after tumor inoculation and cultured lymphocytes were infused IV the following day (day 7). Mean tumor sizes +/− standard error are charted over time (in time points which represent a 2–3 day time period).

(a) Adoptive immunotherapy (AIT) against 4T1 subcutaneous tumors with T cells activated with B/I and cultures in IL-2, IL-21, IL-2/21, IL-7/15, IL-7/15/21. Recipient BALB/c mice were injected in the flank with 10⁴ 4T1 cells and randomized into seven treatment groups: untreated control, cyclophosphamide (CYP)-only (100 mg/kg), and CYP + AIT with B/I activated DLN cells from 4T1-sensitized BALB/c mice cultured in IL-2, IL-21, IL-2/21, IL-7/15 or IL-7/15/21 (50 × 10⁶ cells/mouse). CYP was given 3 days after tumor inoculation and cultured lymphocytes were infused intravenously (IV) the following day (day 4). Mean tumor sizes +/− standard error are charted over time (in days). Numbers in parentheses to the right indicate the number of mice with complete tumor regression (cure) per total number of mice in each group; (b) Adoptive immunotherapy (AIT) against 4T1 subcutaneous tumors with T cells activated with B/I and cultures in IL-2, IL-21, IL-2/21, IL-7/15, IL-7/15/21 at a lower dose (10 million cells/mouse), averaged over three experiments. Recipient BALB/c mice were injected in the flank with 10⁴ 4T1 cells and randomized into seven treatment groups: untreated control, cyclophosphamide (CYP)-only (100 mg/kg), and CYP + AIT with B/I activated DLN cells from 4T1-sensitized BALB/c mice cultured in IL-2, IL-21, IL-2/21, IL-7/15 or IL-7/15/21 (10 × 10⁶ cells/mouse). CYP was given 3 days after tumor inoculation and cultured lymphocytes were infused IV the following day (day 4). Mean tumor sizes +/− standard error are charted over time (in time points which represent a 2–3 day time period); (c) Adoptive immunotherapy (AIT) against 4T1 subcutaneous tumors with T cells activated with B/I and cultures in IL-2, IL-21, IL-2/21, IL-7/15, IL-7/15/21 with initial larger tumor (7 day tumor) averaged over two experiments. Recipient BALB/c mice were injected in the flank with 10⁴ 4T1 cells and randomized into seven treatment groups: untreated control, cyclophosphamide (CYP)-only (100 mg/kg), and CYP + AIT with B/I activated DLN cells from 4T1-sensitized BALB/c mice cultured in IL-2, IL-21, IL-2/21, IL-7/15 or IL-7/15/21 (10 × 10⁶ cells/mouse). CYP was given 6 days after tumor inoculation and cultured lymphocytes were infused IV the following day (day 7). Mean tumor sizes +/− standard error are charted over time (in time points which represent a 2–3 day time period).